Seroprevalence of anti–SARS-CoV-2 IgG antibodies in Kenyan blood donors
Sophie Uyoga(Kenya Medical Research Institute), George M. Warimwe(Kenya Medical Research Institute), J. Anthony G. Scott(Kenya Medical Research Institute), Kadondi Kasera(Ministry of Health), Sammy Kihara(Kenya National Blood Transfusion Services), Mark Otiende(Kenya Medical Research Institute), E. Wangeci Kagucia, Charles N. Agoti(Kenya Medical Research Institute), Rashid Aman(King Abdullah University of Science and Technology), Edwine Barasa(Angkor Hospital for Children), Khamisi Kithi(Kenya National Blood Transfusion Services), Zonia N. Mupe(Kenya Medical Research Institute), Lynette Isabella Ochola‐Oyier(University of Nairobi), Charles Rombo(Kenya National Blood Transfusion Services), Benjamin Tsofa(Kenya Medical Research Institute), Leonard Ndwiga(Kenya Medical Research Institute), Daisy Mugo(Kenya Medical Research Institute), Mercy Mwangangi(Ministry of Health), Edward Otieno(Kenya Medical Research Institute), Christine Yegon(Kenya National Blood Transfusion Services), Shirine Voller(Kenya Medical Research Institute), Elizabeth Odhiambo(Kenya National Blood Transfusion Services), Henry Karanja(Universidade Federal do Rio Grande do Sul), Daniel Wright(University of Oxford), Thomas Rotich(Kenya National Blood Transfusion Services), James Tuju(Kenya Medical Research Institute), Patrick Amoth(Ministry of Health), Wangari Ng’ang’a(Kenya School of Government), Christian Bottomley(London School of Hygiene & Tropical Medicine), Anthony Etyang(Kenya Medical Research Institute), Perpetual Wanjiku(Kenya Medical Research Institute), John N. Gitonga(Universidade Federal do Rio Grande do Sul), Katherine E. Gallagher(Kenya Medical Research Institute), James Nyagwange(Kenya Medical Research Institute), Ifedayo Adetifa(London School of Hygiene & Tropical Medicine), Irene Orgut(Kenya National Blood Transfusion Services), Teresa Lambe(Science Oxford), Ambrose Agweyu(Kenya Medical Research Institute), Philip Bejon(Nuffield Orthopaedic Centre)
Cited by 353
Related Papers
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
|The Lancet|2020|2.6k
Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016
|The Lancet Infectious Diseases|2018|2k
RNA virus interference via CRISPR/Cas13a system in plants
|Genome biology|2018|1.5k